HRP20231084T1 - Bakterije koje proizvode serotonin - Google Patents
Bakterije koje proizvode serotonin Download PDFInfo
- Publication number
- HRP20231084T1 HRP20231084T1 HRP20231084TT HRP20231084T HRP20231084T1 HR P20231084 T1 HRP20231084 T1 HR P20231084T1 HR P20231084T T HRP20231084T T HR P20231084TT HR P20231084 T HRP20231084 T HR P20231084T HR P20231084 T1 HRP20231084 T1 HR P20231084T1
- Authority
- HR
- Croatia
- Prior art keywords
- lactobacillus
- strain
- bacterial strain
- serotonin
- disease
- Prior art date
Links
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title claims 30
- 229940076279 serotonin Drugs 0.000 title claims 15
- 241000894006 Bacteria Species 0.000 title claims 12
- 230000001580 bacterial effect Effects 0.000 claims 17
- 241000186660 Lactobacillus Species 0.000 claims 13
- 229940039696 lactobacillus Drugs 0.000 claims 13
- 241000186604 Lactobacillus reuteri Species 0.000 claims 10
- 229940001882 lactobacillus reuteri Drugs 0.000 claims 9
- 241000394636 Lactobacillus mucosae Species 0.000 claims 8
- 239000001963 growth medium Substances 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims 6
- 102100036465 Autoimmune regulator Human genes 0.000 claims 6
- 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 claims 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 6
- 201000009771 autoimmune polyendocrine syndrome type 1 Diseases 0.000 claims 6
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 6
- 230000007812 deficiency Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 210000002249 digestive system Anatomy 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 206010065687 Bone loss Diseases 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 208000027219 Deficiency disease Diseases 0.000 claims 3
- 208000029725 Metabolic bone disease Diseases 0.000 claims 3
- 206010049088 Osteopenia Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 210000004347 intestinal mucosa Anatomy 0.000 claims 3
- 210000004877 mucosa Anatomy 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010012374 Depressed mood Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- 230000016571 aggressive behavior Effects 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 210000004400 mucous membrane Anatomy 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 230000004793 poor memory Effects 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/045—Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
Claims (15)
1. Postupak odabira bakterijskog soja za upotrebu u liječenju bolesti povezane s manjkom serotonina, pri čemu postupak sadrži:
uzgajanje (S1), u aerobnim uvjetima, bakterija koje pripadaju bakterijskom soju Lactobacillus koji se odabire iz skupine koja se sastoji od bakterijskog soja L. reuteri i bakterijskog soja L. mucosae u mediju za uzgoj kulture koji sadrži triptofan i koji po mogućnosti sadrži izvor ugljika;
otkrivanje (S2) bilo kakvog serotonina koji proizvode bakterije koje pripadaju bakterijskom soju Lactobacillus u mediju za uzgoj kulture ili njegovu uzorku;
utvrđivanje (S15) imaju li bakterije koje pripadaju bakterijskom soju Lactobacillus sposobnost prianjanja na sluznicu crijeva i/ili sposobnost prianjanja na sluznicu probavnog sustava; i
odabiranje (S3) bakterijskog soja Lactobacillus kao učinkovitog u liječenju bolesti povezane s manjkom serotonina u pojedinog ispitanika ako se serotonin otkrije u mediju za uzgoj kulture ili njegovu uzorku i ako bakterije koje pripadaju bakterijskom soju Lactobacillus imaju sposobnost prianjanja na sluznicu crijeva i/ili sposobnost prianjanja na sluznicu probavnog sustava, pri čemu se bolest povezana s manjkom serotonina odabire iz skupine koja se sastoji od anksioznosti, depresivnog raspoloženja, agresije, lošeg pamćenja, poremećaja prehrane, opsesivno-kompulzivnog poremećaja, paničnog poremećaja, posttraumatskog stresnog poremećaja, socijalno anksioznog poremećaja, sindroma iritabilnog kolona (IBS), upalne bolesti crijeva (IBD), kardiovaskularne bolesti, osteoporoze, poremećaja pokretljivosti probavnog sustava, autoimune poliendokrinopatije–kandidijaze-ektodermalne distrofije (APECED), osteopenije i stanja gubitka kostiju.
2. Postupak prema zahtjevu 1, koji nadalje sadrži:
uzgajanje (S10), u anaerobnim uvjetima, bakterija koje pripadaju bakterijskom soju Lactobacillus u mediju za uzgoj kulture koji sadrži triptofan;
otkrivanje (S11) bilo kakvog serotonina koji proizvode bakterije koje pripadaju bakterijskom soju Lactobacillus u mediju za uzgoj kulture ili njegovu uzorku kada se bakterije uzgajaju u anaerobnim uvjetima; i
izračunavanje (S12) omjera koncentracije serotonina otkrivenog u mediju za uzgoj kulture ili njegovu uzorku kada se bakterije uzgajaju u aerobnim uvjetima i koncentracije serotonina otkrivenog u mediju za uzgoj kulture ili njegovu uzorku kada se bakterije uzgajaju u anaerobnim uvjetima, pri čemu
odabiranje (S3) bakterijskog soja Lactobacillus sadrži odabiranje (S3) bakterijskog soja Lactobacillus kao učinkovitog u liječenju bolesti povezane s manjkom serotonina u pojedinog ispitanika ako je omjer jednak ili veći od 1,0, po mogućnosti veći od 1,0, i ako bakterije koje pripadaju bakterijskom soju Lactobacillus imaju sposobnost prianjanja na sluznicu crijeva i/ili sposobnost prianjanja na sluznicu probavnog sustava.
3. Postupak prema bilo kojem zahtjevu od 1 do 2, pri čemu odabiranje (S3) bakterijskog soja Lactobacillus sadrži odabiranje (S3) bakterijskog soja Lactobacillus kao učinkovitog u liječenju bolesti povezane s manjkom serotonina u pojedinog ispitanika ako se serotonin otkrije u mediju za uzgoj kulture ili njegovu uzorku i ako bakterije koje pripadaju bakterijskom soju Lactobacillus imaju sposobnost prianjanja na sluznicu koja je veća od sposobnosti prianjanja na sluznicu bakterijskog soja Lactobacillus reuteri DSM 27131.
4. Soj Lactobacillus reuteri DSM 33509, po mogućnosti u liofiliziranom obliku.
5. Soj Lactobacillus reuteri DSM 33632, po mogućnosti u liofiliziranom obliku.
6. Soj Lactobacillus reuteri DSM 33633, po mogućnosti u liofiliziranom obliku.
7. Soj Lactobacillus reuteri DSM 33634, po mogućnosti u liofiliziranom obliku.
8. Soj Lactobacillus reuteri DSM 33635, po mogućnosti u liofiliziranom obliku.
9. Soj Lactobacillus mucosae DSM 33291, po mogućnosti u liofiliziranom obliku.
10. Soj Lactobacillus mucosae DSM 33292, po mogućnosti u liofiliziranom obliku.
11. Soj Lactobacillus mucosae DSM 33293, po mogućnosti u liofiliziranom obliku.
12. Soj Lactobacillus mucosae DSM 33661, po mogućnosti u liofiliziranom obliku.
13. Soj Lactobacillus reuteri prema bilo kojem zahtjevu od 4 do 8 ili soj Lactobacillus mucosae prema bilo kojem zahtjevu od 9 do 12 za upotrebu u obliku lijeka.
14. Soj Lactobacillus reuteri prema bilo kojem zahtjevu od 4 do 8 ili soj Lactobacillus mucosae prema bilo kojem zahtjevu od 9 do 12 za upotrebu u liječenju bolesti povezane s manjkom serotonina, pri čemu se bolest povezana s manjkom serotonina odabire iz skupine koja se sastoji od anksioznosti, depresivnog raspoloženja, agresije, lošeg pamćenja, poremećaja prehrane, opsesivno-kompulzivnog poremećaja, paničnog poremećaja, posttraumatskog stresnog poremećaja, socijalno anksioznog poremećaja, sindroma iritabilnog kolona (IBS), upalne bolesti crijeva (IBD), kardiovaskularne bolesti, osteoporoze, poremećaja pokretljivosti probavnog sustava, autoimune poliendokrinopatije–kandidijaze-ektodermalne distrofije (APECED), osteopenije i stanja gubitka kostiju.
15. Soj Lactobacillus reuteri za upotrebu ili soj Lactobacillus mucosae za upotrebu prema zahtjevu 14, pri čemu se bolest povezana s manjkom serotonina odabire iz skupine koja se sastoji od sindroma iritabilnog kolona (IBS), upalne bolesti crijeva (IBD), kardiovaskularne bolesti, osteoporoze, poremećaja pokretljivosti probavnog sustava, autoimune poliendokrinopatije–kandidijaze-ektodermalne distrofije (APECED), osteopenije i stanja gubitka kostiju.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1951292 | 2019-11-08 | ||
| PCT/SE2020/051075 WO2021091474A1 (en) | 2019-11-08 | 2020-11-06 | Serotonin producing bacteria |
| EP20807535.8A EP3897836B1 (en) | 2019-11-08 | 2020-11-06 | Serotonin producing bacteria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231084T1 true HRP20231084T1 (hr) | 2023-12-22 |
Family
ID=73449153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231084TT HRP20231084T1 (hr) | 2019-11-08 | 2020-11-06 | Bakterije koje proizvode serotonin |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220354909A1 (hr) |
| EP (2) | EP3897836B1 (hr) |
| JP (1) | JP2023501358A (hr) |
| KR (1) | KR20220094211A (hr) |
| CN (1) | CN114729299B (hr) |
| AU (1) | AU2020379517A1 (hr) |
| BR (1) | BR112022008559A2 (hr) |
| CA (1) | CA3159798A1 (hr) |
| CL (1) | CL2022001042A1 (hr) |
| CO (1) | CO2022005107A2 (hr) |
| EC (1) | ECSP22045408A (hr) |
| ES (1) | ES2961551T3 (hr) |
| HR (1) | HRP20231084T1 (hr) |
| HU (1) | HUE063707T2 (hr) |
| IL (1) | IL292709B2 (hr) |
| MX (1) | MX2022005064A (hr) |
| PL (1) | PL3897836T3 (hr) |
| WO (1) | WO2021091474A1 (hr) |
| ZA (1) | ZA202204539B (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020007987A (es) * | 2018-02-02 | 2020-09-09 | Kobiolabs Inc | Cepa lactobacillus plantarum kbl396 y uso de la misma. |
| CN117187342A (zh) * | 2022-09-27 | 2023-12-08 | 合肥瀚微生物科技有限公司 | 一种基于质谱检测肠道内单个细菌代谢物的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2826808B2 (ja) * | 1995-07-14 | 1998-11-18 | カルピス株式会社 | 脳機能改善、学習能力増強および記憶力増強作用を有する機能性食品 |
| FI126711B (fi) * | 2011-10-12 | 2017-04-13 | Gut Guide Oy | Serotoniinivajeeseen liittyvän terveysriskin arvioiminen |
| WO2016036615A1 (en) * | 2014-09-03 | 2016-03-10 | California Institute Of Technology | Microbe-based modulation of serotonin biosynthesis |
| MA45288A (fr) * | 2016-06-08 | 2019-04-17 | Sofar Spa | Nouvelle utilisation médicale de probiotiques |
| CN107523526B (zh) * | 2017-10-17 | 2020-05-12 | 无限极（中国）有限公司 | 一种罗伊氏乳杆菌及其用途 |
| MX2020007987A (es) * | 2018-02-02 | 2020-09-09 | Kobiolabs Inc | Cepa lactobacillus plantarum kbl396 y uso de la misma. |
-
2020
- 2020-11-06 CA CA3159798A patent/CA3159798A1/en active Pending
- 2020-11-06 AU AU2020379517A patent/AU2020379517A1/en active Pending
- 2020-11-06 EP EP20807535.8A patent/EP3897836B1/en active Active
- 2020-11-06 HR HRP20231084TT patent/HRP20231084T1/hr unknown
- 2020-11-06 JP JP2022526090A patent/JP2023501358A/ja active Pending
- 2020-11-06 MX MX2022005064A patent/MX2022005064A/es unknown
- 2020-11-06 CN CN202080077257.0A patent/CN114729299B/zh active Active
- 2020-11-06 EP EP23186579.1A patent/EP4253571A3/en active Pending
- 2020-11-06 WO PCT/SE2020/051075 patent/WO2021091474A1/en active Search and Examination
- 2020-11-06 HU HUE20807535A patent/HUE063707T2/hu unknown
- 2020-11-06 ES ES20807535T patent/ES2961551T3/es active Active
- 2020-11-06 KR KR1020227018293A patent/KR20220094211A/ko not_active Application Discontinuation
- 2020-11-06 BR BR112022008559A patent/BR112022008559A2/pt unknown
- 2020-11-06 IL IL292709A patent/IL292709B2/en unknown
- 2020-11-06 US US17/623,543 patent/US20220354909A1/en active Pending
- 2020-11-06 PL PL20807535.8T patent/PL3897836T3/pl unknown
-
2022
- 2022-04-22 ZA ZA2022/04539A patent/ZA202204539B/en unknown
- 2022-04-25 CL CL2022001042A patent/CL2022001042A1/es unknown
- 2022-04-25 CO CONC2022/0005107A patent/CO2022005107A2/es unknown
- 2022-06-07 EC ECSENADI202245408A patent/ECSP22045408A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022001042A1 (es) | 2022-11-11 |
| EP3897836A1 (en) | 2021-10-27 |
| CA3159798A1 (en) | 2021-05-14 |
| CO2022005107A2 (es) | 2022-05-10 |
| CN114729299A (zh) | 2022-07-08 |
| MX2022005064A (es) | 2022-05-18 |
| PL3897836T3 (pl) | 2023-10-30 |
| ECSP22045408A (es) | 2022-07-29 |
| KR20220094211A (ko) | 2022-07-05 |
| ES2961551T3 (es) | 2024-03-12 |
| HUE063707T2 (hu) | 2024-01-28 |
| IL292709B1 (en) | 2023-10-01 |
| ZA202204539B (en) | 2023-11-29 |
| BR112022008559A2 (pt) | 2022-08-09 |
| CN114729299B (zh) | 2024-06-18 |
| EP4253571A3 (en) | 2023-12-13 |
| IL292709B2 (en) | 2024-02-01 |
| EP3897836C0 (en) | 2023-08-16 |
| WO2021091474A1 (en) | 2021-05-14 |
| EP4253571A2 (en) | 2023-10-04 |
| US20220354909A1 (en) | 2022-11-10 |
| IL292709A (en) | 2022-07-01 |
| AU2020379517A1 (en) | 2022-05-26 |
| JP2023501358A (ja) | 2023-01-18 |
| EP3897836B1 (en) | 2023-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aviv et al. | Horizontal transfer of the Salmonella enterica serovar Infantis resistance and virulence plasmid pESI to the gut microbiota of warm-blooded hosts | |
| Turpin et al. | Lactobacillaceae and cell adhesion: genomic and functional screening | |
| Jakava-Viljanen et al. | Isolation of surface (S) layer protein carrying Lactobacillus species from porcine intestine and faeces and characterization of their adhesion properties to different host tissues | |
| Bergström et al. | Nature of bacterial colonization influences transcription of mucin genes in mice during the first week of life | |
| Koll et al. | Screening and evaluation of human intestinal lactobacilli for the development of novel gastrointestinal probiotics | |
| Mahony et al. | Host recognition by lactic acid bacterial phages | |
| Strauss et al. | Phenotypic and genotypic analyses of clinical Fusobacterium nucleatum and Fusobacterium periodonticum isolates from the human gut | |
| HRP20231084T1 (hr) | Bakterije koje proizvode serotonin | |
| McWhorter et al. | Comparative phenotypic and genotypic virulence of Salmonella strains isolated from Australian layer farms | |
| Botthoulath et al. | Identification and in vitro assessment of potential probiotic characteristics and antibacterial effects of Lactobacillus plantarum subsp. plantarum SKI19, a bacteriocinogenic strain isolated from Thai fermented pork sausage | |
| Xiong et al. | Arginine deiminase pathway is far more important than urease for acid resistance and intracellular survival in Laribacter hongkongensis: a possible result of arc gene cassette duplication | |
| Volf et al. | Salmonella enterica serovar Typhimurium and Enteritidis infection of pigs and cytokine signalling in palatine tonsils | |
| Yu et al. | A comparative characterization of different host-sourced Lactobacillus ruminis strains and their adhesive, inhibitory, and immunomodulating functions | |
| Drago et al. | Macrolide resistance and in vitro selection of resistance to antibiotics in Lactobacillus isolates | |
| Isenring et al. | Bistable auto-aggregation phenotype in Lactiplantibacillus plantarum emerges after cultivation in in vitro colonic microbiota | |
| Zhang et al. | Screening and evaluation of lactic acid bacteria with probiotic potential from local Holstein raw milk | |
| Breyer et al. | Characterization of lactic acid bacteria in raw buffalo milk: a screening for novel probiotic candidates and their transcriptional response to acid stress | |
| Heo et al. | Comparative genome analysis and evaluation of probiotic characteristics of Lactobacillus plantarum strain JDFM LP11 | |
| Sauvaitre et al. | Role of mucus-bacteria interactions in Enterotoxigenic Escherichia coli (ETEC) H10407 virulence and interplay with human microbiome | |
| Feng et al. | Diversity and evolution of Lactobacillus casei group isolated from fermented dairy products in Tibet | |
| Rodriguez‐Alonso et al. | Antibiotic resistance in lactic acid bacteria and Micrococcaceae/Staphylococcaceae isolates from artisanal raw milk cheeses, and potential implications on cheese making | |
| Zhou et al. | Probiotic potential analysis and safety evaluation of Enterococcus durans A8-1 isolated from a healthy Chinese infant | |
| Rocchetti et al. | Immunomodulatory activity on human macrophages by cell-free supernatants to explore the probiotic and postbiotic potential of Lactiplantibacillus plantarum strains of plant origin | |
| Janda | Taxonomic update on proposed nomenclature and classification changes for bacteria of medical importance, 2013–2014 | |
| Dash et al. | Biochemical, functional and genomic characterization of a new probiotic Ligilactobacillus salivarius F14 from the gut of tribes of Odisha |